Prevention of P. Vivax Malaria During Pregnancy in Bolivia

May 21, 2013 updated by: Bernadette Murgue, Institut de Recherche pour le Developpement

Prevention of P. Vivax Malaria During Pregnancy: Effects on Mother and Child Health in Santa Cruz, Bolivia. Open, Multicentric, Randomized Clinical Trial, Comparing Prophylaxis Once a Week to Malaria Attack Treatment, Both by Chloroquine.

The purpose of this study is to determine which, between weekly prophylaxis or malaria attack treatment, both by chloroquine, is the most appropriate way to protect women and foetus from P. vivax malaria infection during pregnancy.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

It has been demonstrated that malaria is responsible for anaemia during pregnancy and reduces birth weight among newborns. In Bolivia, malaria is mostly caused by P. vivax. Maternal and foetal consequences of P. vivax infections have been poorly investigated until now, over all in South America. In fact, recommendations for the protection of pregnant women from malaria in Bolivia have not been clearly established. Prophylaxis by chloroquine is still recommended in other continents than Africa, mainly because chloroquine resistances are still uncommon in P. vivax species. The alternative way to protect women during pregnancy is to treat malaria attacks during antenatal visits. For this purpose, we will realize a study in order to assess the most appropriate way to protect women and foetus from malaria infection, i.e. weekly prophylaxis or mild malaria attack treatment, both by chloroquine. By realizing a randomized and multicentric clinical trial on 800 women in each group, we will compare the impact on maternal malaria attack incidence rates, on proportions of mothers with anaemia, on low-birth weight and on positive parasitaemias during pregnancy and at delivery, of weekly prophylaxis and mild malaria attack diagnosis and treatment. The study will be undertaken during 18 months in the region of Santa Cruz and will give important information to the Bolivian Ministry of Health for establishing national recommendations.

Study Type

Interventional

Phase

  • Phase 4

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Pregnancy between 4 to 36 weeks of gestation
  • Intention to deliver at the maternity clinics
  • Residence near the maternity clinics
  • Written informed consent (parents or tutors if aged<18 years)

Exclusion Criteria:

  • Pregnancy prior to 4 weeks or after 36 weeks of gestation
  • Allergy to chloroquine
  • Clinical signs of hepatic or renal alteration
  • Inability to take drugs by oral route
  • Presence of effective uterine contractions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Chloroquine profilaxis

Prevention: chloroquine profilaxis

Prevention of malaria attacks with chloroquine profilaxis taken once a week

Prevention:

Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes

Other Names:
  • prevention of plasmodium vivax malaria harmfull effects on birth outcomes
No Intervention: No prevention
Treatment of malaria attack with chloroquine when they occur

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of women presenting a malaria attack during pregnancy
Time Frame: two years
two years

Secondary Outcome Measures

Outcome Measure
Time Frame
proportions of mothers with placental plasmodial infection
Time Frame: 2 years
2 years
proportions of mothers with moderate to severe anaemia (<8g/dl) at delivery
Time Frame: 2 years
2 years
maternal haemoglobin rate at delivery
Time Frame: 2 years
2 years
proportions of women with parasitaemia during pregnancy and at delivery
Time Frame: 2 years
2 years
mean parasites densities of women with parasitaemia during pregnancy and at delivery
Time Frame: 2 years
2 years
proportions of children with low birthweight (<2,500 grams)
Time Frame: 2 years
2 years
mean birthweight
Time Frame: 2 years
2 years
proportions of preterm deliveries
Time Frame: 2 years
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Michel Cot, MD-PhD, Institut de Recherche pour le Developpement
  • Study Director: Laurent Brutus, MD-MSc, Institut de Recherche pour le Développement, IRD, Bolivia
  • Principal Investigator: Agnès Le Port, MSc, Institut de Recherche pour le Développement, IRD, Bolivia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2006

Primary Completion (Anticipated)

November 1, 2007

Study Completion (Anticipated)

November 1, 2007

Study Registration Dates

First Submitted

February 9, 2006

First Submitted That Met QC Criteria

February 9, 2006

First Posted (Estimate)

February 13, 2006

Study Record Updates

Last Update Posted (Estimate)

May 22, 2013

Last Update Submitted That Met QC Criteria

May 21, 2013

Last Verified

May 1, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe